Jean-Francois Rahier
Overview
Explore the profile of Jean-Francois Rahier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cremer A, Rosewick N, Kelsey M, Trepo E, Libert F, De Vos M, et al.
J Crohns Colitis
. 2025 Feb;
19(3).
PMID: 39945142
Background And Aims: Inflammatory bowel disease (IBD) is associated with a higher risk of developing colorectal cancer, according to the inflammation-dysplasia-cancer (IDC) sequence from inflammation to colitis-associated colorectal cancer (CAC)....
2.
Sarti K, Nollevaux M, Rahier J
Dig Liver Dis
. 2024 Nov;
57(2):640-641.
PMID: 39578162
No abstract available.
3.
Druez A, Travis S, Rahier J
Intest Res
. 2023 Jul;
21(3):411-412.
PMID: 37394417
No abstract available.
4.
Eder P, Verstock B, Culver E, Dragoni G, Kredel L, Wypych J, et al.
J Crohns Colitis
. 2023 Jun;
17(11):1791-1799.
PMID: 37283545
Background: Autoimmune pancreatitis [AIP] is rarely associated with inflammatory bowel disease [IBD]. The long-term outcomes of AIP and IBD in patients with coexisting AIP-IBD and predictors of complicated AIP course...
5.
Vieujean S, Moens A, Hassid D, Rothfuss K, Savarino E, Vavricka S, et al.
J Crohns Colitis
. 2022 Oct;
17(4):472-479.
PMID: 36223253
Background And Aim: Pneumocystis jirovecii pneumonia [PJP] is a very rare, potentially life-threatening pulmonary fungal infection that occurs in immunocompromised individuals including patients with inflammatory bowel disease [IBD]. Our aim...
6.
Peyrin-Biroulet L, Rahier J, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, et al.
Clin Gastroenterol Hepatol
. 2022 Sep;
21(3):771-788.e10.
PMID: 36152897
Background And Aims: There is a need to evaluate the benefit-risk ratio of current therapies in inflammatory bowel disease (IBD) patients to provide the best quality of care. The primary...
7.
Olivera P, Lasa J, Zubiaurre I, Jairath V, Abreu M, Rubin D, et al.
J Crohns Colitis
. 2022 Sep;
17(2):199-210.
PMID: 36087107
Background And Aims: Advanced therapies for inflammatory bowel disease [IBD] could potentially lead to a state of immunosuppression with an increased risk of opportunistic infections [OIs]. We aimed to provide...
8.
Truyens M, Lobaton T, Ferrante M, Bossuyt P, Vermeire S, Pouillon L, et al.
Gastroenterology
. 2022 Aug;
163(5):1294-1305.e3.
PMID: 35940251
Background & Aims: Fatigue is highly prevalent among patients with inflammatory bowel disease (IBD), and only limited treatment options are available. Based on the hypothetical link between low serum tryptophan...
9.
Amiot A, Rahier J, Baert F, Nahon S, Hart A, Viazis N, et al.
J Crohns Colitis
. 2022 Jun;
17(1):37-48.
PMID: 35767639
Background And Aims: There are concerns regarding the potential impact of the COVID-19 outbreak on patients with inflammatory bowel disease [IBD]. We report on the impact of the COVID-19 outbreak...
10.
Delorme A, Lemaire J, Rahier J
Inflamm Bowel Dis
. 2022 Feb;
28(7):e99-e100.
PMID: 35134919
No abstract available.